 Athenex NASDAQ: ATNX stock is rocketing higher on Tuesday thanks to positive results from a high-risk early-stage breast cancer clinical trial. The Phase 2 study covers the use of the companys oral paclitaxel plus encequidar in combination with a PD-1 inhibitor and carboplatin. 